

dengue and dengue hemorrhagic fever

Dengue and Dengue Hemorrhagic Fever: Understanding the Risks and Prevention

dengue and dengue hemorrhagic fever are significant public health concerns, especially in tropical and subtropical regions around the world. These mosquito-borne illnesses affect millions of people annually and can range from mild flu-like symptoms to severe and potentially fatal complications. Understanding what dengue and dengue hemorrhagic fever involve, their symptoms, causes, and prevention strategies is crucial in combating their spread and minimizing their impact on affected communities.

What Is Dengue and Dengue Hemorrhagic Fever?

Dengue fever is caused by the dengue virus, which is transmitted to humans primarily through the bite of infected *Aedes* mosquitoes, particularly *Aedes aegypti* and *Aedes albopictus*. After infection, symptoms usually appear within 4 to 10 days and can last for up to two weeks. While many cases of dengue fever are mild and resolve on their own, some progress to a more severe form known as dengue hemorrhagic fever (DHF), which can be life-threatening without prompt medical attention.

Difference Between Dengue Fever and Dengue Hemorrhagic Fever

While both conditions result from the dengue virus, dengue hemorrhagic fever is characterized by increased vascular permeability, bleeding, and low platelet count, which can lead to shock and organ damage. The severity of DHF makes it critical to recognize early warning signs and seek medical care immediately.

Symptoms and Warning Signs

Recognizing the symptoms of dengue and dengue hemorrhagic fever is key to timely treatment. Symptoms can vary based on the severity of the infection.

Common Symptoms of Dengue Fever

- High fever, often sudden onset
- Severe headaches
- Pain behind the eyes
- Muscle and joint pain (sometimes called "breakbone fever")
- Nausea and vomiting
- Fatigue and weakness
- Skin rash appearing a few days after fever onset

These symptoms typically resolve within a week; however, during recovery, patients may feel unusually tired.

Warning Signs of Dengue Hemorrhagic Fever

DHF usually develops after the initial fever subsides, and early detection can save lives. Symptoms include:

- Severe abdominal pain
- Persistent vomiting
- Bleeding gums or nosebleeds
- Blood in vomit or stool
- Difficulty breathing
- Restlessness or irritability

If any of these signs appear, immediate hospitalization is necessary to prevent complications such as dengue shock syndrome.

Causes and Transmission

The dengue virus has four distinct serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), meaning a person can be infected up to four times in their lifetime. Infection with one serotype provides lifelong immunity to that type but not the others, which complicates prevention efforts.

The Role of Mosquito Vectors

Aedes mosquitoes thrive in urban environments, breeding in stagnant water found in flower pots, discarded tires, buckets, and clogged gutters. These mosquitoes are most active during early morning and late afternoon, and their bites transmit the virus from infected individuals to others.

Factors Contributing to Dengue Outbreaks

Several factors can increase the risk of dengue outbreaks, such as:

- Rapid urbanization without adequate sanitation
- Climate change, which affects mosquito breeding cycles
- Increased international travel spreading the virus to new regions
- Lack of community awareness and preventive measures

Understanding these factors helps public health officials design effective control strategies.

Diagnosis and Treatment

Diagnosing dengue involves recognizing clinical symptoms and confirming with laboratory tests such as blood platelet counts, serological tests detecting dengue antibodies, or PCR tests detecting viral RNA.

Managing Dengue Fever

There is no specific antiviral treatment for dengue. Management focuses on supportive care, which includes:

- Maintaining hydration by drinking plenty of fluids
- Using acetaminophen (paracetamol) to reduce fever and pain (avoiding aspirin and nonsteroidal anti-inflammatory drugs due to bleeding risk)
- Rest and monitoring symptoms closely

Treating Severe Cases of Dengue Hemorrhagic Fever

Hospitalization is often required for DHF cases, where intravenous fluids and close monitoring can prevent shock and organ failure. Blood transfusions may be necessary if severe bleeding occurs. Early medical intervention significantly improves survival rates.

Prevention Strategies

Because there is no widely available vaccine that protects against all dengue serotypes for the general population, prevention largely focuses on mosquito control and personal protective measures.

Community and Environmental Measures

- Eliminate mosquito breeding sites by regularly emptying or covering containers that collect water
- Use larvicides in water storage tanks where draining is not possible
- Implement community clean-up campaigns to reduce mosquito habitats
- Support government vector control programs such as fogging during outbreaks

Personal Protection Tips

- Wear long-sleeved shirts and pants, especially during peak mosquito activity times
- Use mosquito repellents containing DEET, picaridin, or IR3535
- Sleep under mosquito nets if living in or visiting high-risk areas
- Install window and door screens to keep mosquitoes out of living spaces

Global Impact and Ongoing Research

Dengue and dengue hemorrhagic fever represent a growing global health challenge, particularly in regions with inadequate healthcare infrastructure. The World Health Organization estimates that nearly half the world's population lives in areas at risk for dengue transmission, with approximately 100 to 400 million infections each year.

Scientists are actively researching vaccines, antiviral drugs, and innovative mosquito control methods such as genetically modified mosquitoes designed to reduce vector populations. Some vaccines, like Dengvaxia, have been approved in certain countries but come with restrictions due to safety concerns in people not previously infected.

Why Awareness and Education Matter

Public education campaigns are vital in preventing dengue outbreaks. When communities understand how dengue spreads and how to protect themselves, they can take proactive steps to reduce risk. Schools, workplaces, and media outlets play a crucial role in disseminating accurate information.

Living in or traveling to dengue-endemic areas means staying informed and vigilant. Simple actions, when collectively embraced, can drastically reduce the burden of dengue and dengue hemorrhagic fever on individuals and healthcare systems alike.

Frequently Asked Questions

What is the difference between dengue fever and dengue hemorrhagic fever?

Dengue fever is a mosquito-borne viral infection causing flu-like symptoms, while dengue hemorrhagic fever is a severe form of dengue that includes bleeding, blood plasma leakage, and can lead to shock or death if untreated.

What are the common symptoms of dengue fever?

Common symptoms of dengue fever include high fever, severe headache, pain behind the eyes, joint and muscle pain, rash, and mild bleeding such as nose or gum bleeding.

How is dengue hemorrhagic fever diagnosed?

Dengue hemorrhagic fever is diagnosed through clinical evaluation of symptoms like bleeding, low platelet count, and evidence of plasma leakage, confirmed by laboratory tests such as dengue antigen or antibody tests and blood counts.

What are the preventive measures against dengue and dengue hemorrhagic fever?

Preventive measures include eliminating mosquito breeding sites, using mosquito repellents, installing window screens, wearing protective clothing, and community-wide vector control programs.

Is there a vaccine available for dengue fever?

Yes, there is a vaccine called Dengvaxia approved in some countries for individuals who have had a previous dengue infection, but it is not recommended for everyone due to safety concerns. Research for more effective vaccines is ongoing.

Additional Resources

Dengue and Dengue Hemorrhagic Fever: An In-Depth Review of a Global Health Challenge

dengue and dengue hemorrhagic fever represent significant public health concerns, especially in tropical and subtropical regions where the *Aedes* mosquito thrives. These viral infections, caused by the dengue virus, have seen a marked increase in incidence over recent decades, posing challenges for healthcare systems worldwide. Understanding the distinctions between dengue and its severe form, dengue hemorrhagic fever (DHF), alongside their epidemiology, clinical features, and prevention strategies, is crucial for effective disease management and control.

Understanding Dengue and Its Severe Manifestations

Dengue is a mosquito-borne viral infection transmitted primarily by the *Aedes aegypti* and *Aedes albopictus* species. The virus exists in four distinct serotypes (DEN-1, DEN-2, DEN-3, DEN-4), each capable of causing illness. Infection with one serotype provides lifelong immunity against that serotype but not against the others, which partly explains the potential for repeated infections and increased risk of severe disease.

Clinical Presentation and Disease Spectrum

The clinical spectrum of dengue ranges from asymptomatic infection to severe hemorrhagic manifestations. Classic dengue fever typically presents with high fever, severe headache, retro-orbital pain, muscle and joint pains, rash, and mild bleeding tendencies such as nose or gum bleeding. Symptoms generally last for about one week.

Dengue hemorrhagic fever, a more severe form, is characterized by increased vascular permeability, plasma leakage, bleeding, and thrombocytopenia (low platelet count). This can progress to dengue shock syndrome (DSS), a life-threatening condition marked by circulatory failure and shock. The pathophysiology involves complex immune responses, including antibody-dependent enhancement (ADE), where pre-existing antibodies from a previous dengue infection exacerbate the illness upon a subsequent infection with a different serotype.

Global Epidemiology and Trends

According to the World Health Organization (WHO), an estimated 100 to 400 million dengue infections occur annually across more than 125 countries. The disease burden is highest in Southeast Asia, the Western Pacific, the Americas, and parts of Africa. Urbanization, climate change, and increased travel have facilitated the expansion of the *Aedes* mosquito vector, contributing to the rising incidence.

Outbreaks of dengue and dengue hemorrhagic fever typically show seasonal patterns related to rainfall and temperature, which influence mosquito breeding cycles. The expanding geographic distribution of *Aedes* mosquitoes has led to dengue cases appearing in previously non-endemic areas, raising concerns about future epidemic potential.

Diagnostic Challenges and Clinical Management

Early and accurate diagnosis of dengue and dengue hemorrhagic fever is vital to reduce morbidity and mortality. However, overlapping symptoms with other febrile illnesses complicate clinical diagnosis, particularly in resource-limited settings.

Diagnostic Methods

Laboratory confirmation relies on viral detection, serology, or molecular techniques:

- **Virus isolation and PCR:** Detect viral RNA in the acute phase, highly specific but require advanced laboratory infrastructure.
- **NS1 antigen test:** Identifies non-structural protein 1 during early infection, useful for rapid diagnosis.
- **IgM and IgG serology:** Detects antibodies; IgM indicates recent infection, while IgG reflects past exposure. Interpretation must consider potential cross-reactivity with other flaviviruses.

The dynamic nature of the immune response and timing of sample collection influence test sensitivity and specificity.

Treatment Approaches

Currently, no specific antiviral therapy exists for dengue infections. Management is primarily supportive:

- **Fluid management:** Crucial in preventing shock in DHF. Careful monitoring of fluid intake and output is essential to avoid fluid overload or dehydration.

- **Symptomatic relief:** Use of acetaminophen for fever and pain; non-steroidal anti-inflammatory drugs (NSAIDs) are contraindicated due to bleeding risk.
- **Monitoring for complications:** Regular assessment of hematocrit, platelet count, and signs of bleeding or shock.

In severe cases, hospitalization and intensive supportive care can be lifesaving. Blood transfusions or platelet concentrates may be needed to manage significant hemorrhage.

Prevention Strategies and Public Health Implications

Given the lack of curative treatments, prevention remains the cornerstone of dengue control. This involves vector control, public education, and vaccine development.

Vector Control Measures

Reducing mosquito populations and limiting human-mosquito contact are primary strategies:

- **Elimination of breeding sites:** Removal of stagnant water from containers, tires, and other receptacles to prevent mosquito larvae development.
- **Insecticide use:** Application of larvicides and adulticides in endemic areas, though resistance development is a concern.
- **Personal protective measures:** Use of insecticide-treated nets, repellents, and protective clothing, especially during peak mosquito activity.

Community engagement and sustained efforts are essential for effective vector control.

Vaccination Efforts

The development of a safe and effective dengue vaccine has been challenging due to the virus's serotypic diversity and risk of ADE. Dengvaxia (CYD-TDV), the first licensed dengue vaccine, is currently approved in several countries for individuals with prior dengue infection. Its use is limited because vaccination in seronegative individuals may increase the risk of severe dengue upon subsequent infection.

New vaccine candidates, including live attenuated and recombinant vaccines, are in various stages of clinical trials, showing promise in broader protective efficacy and safety profiles.

Socioeconomic and Environmental Factors Influencing Disease Dynamics

Dengue and dengue hemorrhagic fever disproportionately affect urban and peri-urban populations in low- and middle-income countries. Rapid unplanned urbanization creates breeding grounds for *Aedes* mosquitoes, while inadequate water supply and waste management exacerbate the problem.

Climate change also plays a significant role by extending the mosquito breeding season and expanding their geographic range. Warmer temperatures shorten the extrinsic incubation period of the virus in mosquitoes, potentially increasing transmission rates.

Public health interventions must therefore consider these broader determinants to develop sustainable and context-specific strategies.

Comparative Analysis with Other Arboviral Diseases

Dengue shares transmission vectors and clinical similarities with other arboviral diseases such as Zika and chikungunya. Co-circulation of these viruses complicates diagnosis and surveillance. Unlike dengue hemorrhagic fever, chikungunya primarily causes severe joint pain, while Zika infection is linked to congenital abnormalities.

Integrated vector management and enhanced laboratory capacity are needed to address these overlapping threats effectively.

The evolving epidemiology of dengue and dengue hemorrhagic fever underscores the importance of multidisciplinary approaches encompassing clinical care, vector ecology, public health policy, and community participation. Advances in diagnostic technologies, vaccine development, and vector control methodologies offer hope but require coordinated global efforts to mitigate the impact of these pervasive diseases.

[Dengue And Dengue Hemorrhagic Fever](#)

Find other PDF articles:

<https://old.rga.ca/archive-th-098/Book?trackid=LJK00-0282&title=adding-positive-and-negative-integers-worksheets.pdf>

dengue and dengue hemorrhagic fever: Dengue and Dengue Hemorrhagic Fever, 2nd Edition Duane J. Gubler, Eng Eong Ooi, Subhash Vasudevan, Jeremy Farrar, 2014-08-29 Continued geographic expansion of dengue viruses and their mosquito vectors has seen the magnitude and frequency of epidemic dengue/dengue hemorrhagic fever (DF/DHF) increase dramatically. Recent exciting research on dengue has resulted in major advances in our understanding of all aspects of the biology of these viruses, and this updated second edition brings together leading research and

clinical scientists to review dengue virus biology, epidemiology, entomology, therapeutics, vaccinology and clinical management.

dengue and dengue hemorrhagic fever: Dengue Fever and Other Hemorrhagic Viruses

Tirtha Chakraborty, I. Edward Alcamo, 2008 Dengue fever is an infectious disease found around the world that is caused by four closely related, but distinct, types of viruses commonly transmitted by *Aedes aegypti* mosquitoes. Triggering excessive bleeding, dengue fever, dengue hemorrhagic fever, and dengue hemorrhagic shock can be fatal. *Dengue Fever and Other Hemorrhagic Viruses* explores the biology of the dengue virus and similar viruses such as Ebola, Marburg virus, and Lassa fever, as well as their symptoms, where they are commonly found, how they are transmitted, and the efforts to treat and eradicate them. Chapters include: Ins and Outs of Dengue; Hemorrhagic Fevers; Vectors - Bugs That Carry Disease; The Immune System: Our Line of Defense; and, Vaccination - Waking Up the Army in Us.

dengue and dengue hemorrhagic fever: Dengue and Dengue Hemorrhagic Fever , 2012

dengue and dengue hemorrhagic fever: Dengue and Dengue Hemorrhagic Fever in the Americas Pan American Sanitary Bureau, 1994 Dengue and its potentially fatal forms, dengue hemorrhagic fever and dengue shock syndrome, once more threaten much of the Americas. In the 1980s the vector control programmes fell victim to the cutbacks in public health expenditure and their responses to dengue outbreaks tended to be a little too late. These guidelines have risen to the challenge by incorporating all aspects of the prevention and control of the disease and its vectors. In addition, because dengue is primarily a problem of domestic sanitation and households can combat the problem inexpensively. The guidelines emphasize ways to transfer responsibility for dengue control and prevention to the community.

dengue and dengue hemorrhagic fever: Dengue and Dengue Hemorrhagic Fever , 1986

dengue and dengue hemorrhagic fever: Journal of the Medical Association of Thailand , 2008-10 The journal of Medical Association of Thailand publishes original and review articles including case report that relate to the study or research on diseases, epidemiology, drug or vaccine that have the influence on clinical course, treatment and prevention of human illness

dengue and dengue hemorrhagic fever: New Treatment Strategies for Dengue and Other Flaviviral Diseases Gregory R. Bock, Jamie A. Goode, 2006-10-02 Dengue virus is a member of the Flaviviridae family, which includes viruses associated with human diseases such as yellow fever, Japanese encephalitis and hepatitis C. Dengue fever is transmitted by mosquitoes, principally *Aedes aegypti*. There are four serotypes of dengue virus, of which DENV-2 has been the most prevalent in many recent epidemics. Following primary infection, lifelong immunity develops, preventing repeated assault by the same serotype. However, the non-neutralizing antibodies from a previous infection or maternally acquired antibodies are thought to form complexes with a different serotype during a subsequent infection and cause dengue haemorrhagic fever/dengue shock syndrome, which can be fatal. There is no treatment or vaccine available today that can combat this emerging and uncontrolled disease. This book features contributions from the world's leading researchers working on dengue and related flaviviruses who examine the current state of the art in the molecular biology of the dengue virus. Particular emphasis is placed on the structure and function of the virus and the targeting of virus proteins by potential antiviral agents. The pathogenesis of dengue and dengue haemorrhagic fever are discussed in detail, especially the target cells and the specific receptors on these cells, thereby developing a clear overview of host and viral factors that contribute to dengue haemorrhagic fever. Finally, the book reviews the therapeutic options, paying particular attention to ways in which vector, host and environment can play a critical role in the spread of this disease. With dengue fever and other emerging viral diseases becoming increasingly prevalent around the world, this book provides valuable insight into the virus that causes this disease and potential ways to manage it. It is essential reading for all those working in tropical diseases, public health and virology. Praise from the reviews: The book provides an excellent summary of dengue/flavivirus research and is important for individuals and institutions interested in emerging infectious diseases.

MICROBIOLOGY TODAY

dengue and dengue hemorrhagic fever: Advances in Virus Research , 1999-10-20 Advances in Virus Research

dengue and dengue hemorrhagic fever: Monograph on Dengue/dengue Haemorrhagic Fever Prasert Thongcharoen, 1993 Contributed articles.

dengue and dengue hemorrhagic fever: Dengue and Dengue Hemorrhagic Fever D. Peter Drotman, 2005-07-01 Contents: Persistent Emergence of Dengue, by C.H. Calisher; More Dengue, More Questions, by S.B. Halstead; Dengue Fever, Hawaii, 2001-2002, by P.V. Effler et al; Dengue Risk Among Visitors to Hawaii, by C.E. Smith et al.; Dengue Type 3 Virus, Saint Martin (Martinique), 2003-2004, C.N. Peyrefitte et al; Dengue Antibody Prevalence in German Travelers, by O. Wichmann et al; Leptospirosis During Dengue Outbreak, Bangladesh, by R.C. LaRocque et al; & Retinal Hemorrhage in Patients with Dengue Fever, by M.P. Chlebicki et al. Illustrations.

dengue and dengue hemorrhagic fever: Dengue Viruses R.W. Schlesinger, 2012-12-06 2. Virological Findings. 90 3. Immunity. . . . 90 C. Secondary Dengue: Dengue Hemorrhagic Fever and the Shock Syndrome 92 1. General Remarks. 92 2. Clinical Course and Clinical Laboratory Findings 93 3. Virological and Serological Findings. . . 95 4. Immunopathology of Secondary Dengue. 98 XI. Immunization. 104 A. Anamnestic Immune Responses in Sequential Infections With Dengue and Other Group B Togaviruses 104 1. Results With Members of the Dengue Subgroup 104 2. Results With Dengue and Other Flaviviruses. 107 B. Dengue Vaccines for Use in Man 108 XII. Opportunities for the Future 113 Acknowledgments. 114 References. 114 I. Introduction Dengue fever is a mosquito-transmitted disease of man which has afflicted untold millions of people over the past two centuries. It is caused by viruses classified as a subgroup of the group B togaviruses. Along with other members of that group as well as group A, the dengue viruses have been investigated intensively during recent years. Certain unique aspects of their structure, composition, antigenicity, replication, and antigenic relationships have established the togavirus family as quite distinct from other families of enveloped RNA viruses (see recent review of PFEFFERKORN and SHAPIRO, 1974). The basic studies leading to this conclusion have coincided with epidemiological field investigations which have resulted in a continuing increase in the number of viruses now designated as group A or B togaviruses. This, in turn, has led to a growing appreciation of their immense importance as actual or potential pathogens of man and beast.

dengue and dengue hemorrhagic fever: Handbook of Zoonoses, Section B George W. Beran, 2017-12-06 This multivolume handbook presents the most authoritative and comprehensive reference work on major zoonoses of the world. The Handbook of Zoonoses covers most diseases communicable to humans, as well as those diseases common to both animals and humans. It identifies animal diseases that are host specific and reviews the effects of various human diseases on animals. Discussions address diseases that remain important public and animal health problems and the techniques that can control and prevent them. The chapters are written by internationally recognized scientists in their respective areas of disease, who work or have worked extensively in the most affected areas of the world. The emphasis for each zoonosis is on the epidemiology of the disease, the clinical syndromes and carrier states in infected animals and humans, and the most current methods for diagnosis and approaches to control. For infectious agents or biologic toxins, which may be transmitted by foods of animal origin, a strong focus is placed on food safety measures. The etiologic and therapeutic aspects of each disease important to epidemiology and control are identified.

dengue and dengue hemorrhagic fever: Dengue Fever in a One Health Perspective , 2020-10-28 Dengue Fever in a One Health Perspective underlines important aspects of dengue virus, the most prevalent and life-threatening arbovirus in the world. Over three sections, chapters cover such topics as biological and environmental aspects, physiopathology, molecular biology, diagnosis, and control strategies. The first section provides knowledge on basic aspects of dengue virus biology and its emergence and re-emergence associated to environmental changes. The second section includes two chapters on dengue immunopathology, a drawback in disease control and vaccine

development. Finally, the third section examines molecular biology tools employed in dengue virus immunopathogenesis studies, diagnosis, drug design, and in the use of vectors as sentinels in surveillance and vector biology studies.

dengue and dengue hemorrhagic fever: Congenital and Perinatal Infections Cecelia Hutto, Gwendolyn B. Scott, 2007-10-28 A concise clinical reference that facilitates the diagnosis of intrauterine and perinatally acquired infections was the goal in creating the Congenital and Perinatal Infections: A Concise Guide to Diagnosis. Information about the natural history, management, and outcome of these infections is well detailed in many other sources and so has not been included. Rather, the focus of the book is diagnosis. The initial chapters provide general information about serological and nonserological assays that are used for the diagnosis of infections, and a chapter about the placenta includes details about histopathological findings that can be helpful with the diagnosis of congenital infections. The remainder of the book is devoted to the diagnosis of specific congenital and/or perinatal infections. As illustrated in the chapters about specific infections, the approach to diagnosis of a congenital or perinatally acquired infection in the neonate begins, when possible, with consideration and diagnosis of infection in the pregnant woman, knowledge of how the infection is transmitted, and the risk of that infection for the woman and her fetus or neonate. The possibility of congenital or perinatal infection in neonates is usually considered because of the diagnosis of, or concern about a specific infection in, a mother during pregnancy that can be transmitted to the neonate or because of clinical findings in the neonate at birth that suggest an infectious cause.

dengue and dengue hemorrhagic fever: Disease Sheet: Dengue and Dengue Haemorrhagic Fever, 1995 Presents an online, full text fact sheet entitled, Dengue and Dengue Haemorrhagic Fever. Notes that the document was published in August 1995, by the Division of Control of Tropical Diseases (CTD), which is part of the World Health Organization (WHO) in Geneva, Switzerland. Explains that dengue and dengue hemorrhagic fever (DHF) are mosquito-borne diseases. Discusses the prevention of the diseases. Includes information in English, Portuguese, Spanish, and French. Links to the home pages of CTD and WHO.

dengue and dengue hemorrhagic fever: The Flaviviruses: Detection, Diagnosis and Vaccine Development, 2003-12-18 Over 50% of known flaviviruses have been associated with human disease. The Flavivirus genus constitutes some of the most serious human pathogens including Japanese encephalitis, dengue and yellow fever. Flaviviruses are known for their complex life cycles and epidemic spread, and are considered a globally-emergent viral threat. Detection, Diagnosis and Vaccine Development, the third volume of The Flaviviruses details the current status of technologies for detection and differentiation of these viruses, their use in surveillance and outbreak investigation, and also reviews the latest clinical research. - Comprehensive approach to the scientific disciplines needed to unravel the complexities of virus-host interactions - Describes the technologies that have contributed to our current knowledge about the Flaviviruses - Identifies the major problems faced in understanding the virus-host interactions that result in disease - An exhaustive compendium of current and past knowledge on the Flavivirus family

dengue and dengue hemorrhagic fever: Emerging Infectious Diseases Felissa R. Lashley, Jerry D. Durham, 2007-05-14 This new work updates the highly regarded first edition...and is equally excellent. It offers a wealth of timely information about a variety of emerging and reemerging infections...This is an excellent reference for anyone interested in emerging infections, and will be a valuable resource for health science students, especially those in nursing and public health....Highly recommended. Upper-level undergraduates through professionals/practitioners.--Choice Emerging, re-emerging, and antibiotic-resistant infectious diseases continue to increase at an alarming rate throughout the world. Written for a wide range of health professionals, particularly nurses, this revised edition provides a comprehensive and up-to-date overview of these diseases: their epidemiology, clinical manifestations, prevention, and treatment. With contributions by a multidisciplinary team of nurses, physicians, and infectious disease specialists, the book includes material on the most recent and important new emerging infectious diseases: Avian influenza and

SARS Issues of demographics and microbial resistance Special topics, including bioterrorism Behavioral and cultural factors Infectious etiologies of chronic diseases Travel and recreational exposure Each chapter is amply illustrated with clinical case examples to demonstrate the pitfalls in differential diagnosis and elucidate proper management and treatment. Valuable appendices provide critical reference information for each of the bacterial, viral, fungal, and parasitic diseases.

dengue and dengue hemorrhagic fever: Dengue Virus Alan L. Rothman, 2010-04-29

Scientific research on dengue has a long and rich history. The literature has been touched by famous names in medicine- Benjamin Rush, Walter Reed, and Albert Sabin, to name a very few- and has been fertile ground for medical historians . The advances made in those early investigations are all the more remarkable for the limited tools available at the time. The demonstration of a viral etiology for dengue fever, the recognition of mosquitoes as the vector for transmission to humans, and the existence of multiple viral variants (serotypes) with only partial cross-protection were all accomplished prior to the ability to culture and characterize the etiologic agent. Research on dengue in this period was typically driven by circumstances. Epidemics of dengue created public health crises, although these were relatively short-lived in any one location, as the population of susceptible individuals quickly shrank. Military considerations became as a major driving force for research. With the introduction of large numbers of non-immune individuals into endemic areas, dengue could cripple military readiness, taking more soldiers out of action than hostile fire. Dengue and dengue hemorrhagic fever, which assumed pandemic proportions during the latter half of the last century, have shown no indication of slowing their growth during this first decade of the twenty-first century. Challenges remain in understanding the basic mechanisms of viral replication and disease pathogenesis, in clinical management of patients, and in control of dengue viral transmission. Nevertheless, new tools and insights have led to major recent scientific advances. As the first candidate vaccines enter large-scale efficacy trials, there is reason to hope that we may soon turn the corner on this disease.

dengue and dengue hemorrhagic fever: Dengue and Dengue Hemorrhagic Fever , 1986*

dengue and dengue hemorrhagic fever: Emerging Infectious Diseases , 2012

Related to dengue and dengue hemorrhagic fever

Dengue - World Health Organization (WHO) WHO fact sheet on dengue, providing information on symptoms, diagnostics and treatment, global burden, transmission, risk factors, prevention and control and WHO's work in

Dengue y dengue grave - World Health Organization (WHO) El dengue es una infección vírica transmitida por mosquitos. En las últimas décadas ha aumentado enormemente la incidencia de dengue en el mundo

Dengue and severe dengue - World Health Organization (WHO) Dengue is a self-limiting febrile illness with symptoms ranging from extremely mild (asymptomatic) to severe. Symptoms of dengue may be observed around 4-10 days after the

Dengue and severe dengue - World Health Organization (WHO) Dengue is a mosquito-borne viral infection that causes a severe flu-like illness and sometimes a potentially lethal complication called severe dengue. The incidence of dengue

Dengue Fever - National Institute of Allergy and Infectious Dengue fever is an infectious disease carried by mosquitoes and caused by any of four related dengue viruses. This disease used to be called "break-bone" fever because it sometimes

Dengue - Global situation - World Health Organization (WHO) Dengue virus is transmitted to humans through the bite of infected mosquitoes typically in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.

¿Qué es el dengue y cómo se trata? - World Health Organization El dengue grave es una complicación potencialmente mortal, pero su diagnóstico clínico precoz y una atención clínica cuidadosa por personal médico y de enfermería experimentado suele

Dengue and severe dengue WPRO - World Health Organization Dengue is a viral infection

transmitted to humans through the bite of infected mosquitoes, primarily through *Aedes aegypti* mosquitoes and, to a lesser extent, *Aedes*

Dengue- Global situation - World Health Organization (WHO) The global incidence of dengue has markedly increased over the past two decades, posing a substantial public health challenge.

From 2000 to 2019, the World Health

Dengue - Situación mundial El dengue es una enfermedad vírica que se transmite al ser humano por la picadura de mosquitos infectados, típicamente en climas tropicales y subtropicales de todo el mundo,

Dengue - World Health Organization (WHO) WHO fact sheet on dengue, providing information on symptoms, diagnostics and treatment, global burden, transmission, risk factors, prevention and control and WHO's work in

Dengue y dengue grave - World Health Organization (WHO) El dengue es una infección vírica transmitida por mosquitos. En las últimas décadas ha aumentado enormemente la incidencia de dengue en el mundo

Dengue and severe dengue - World Health Organization (WHO) Dengue is a self-limiting febrile illness with symptoms ranging from extremely mild (asymptomatic) to severe. Symptoms of dengue may be observed around 4–10 days after the

Dengue and severe dengue - World Health Organization (WHO) Dengue is a mosquito-borne viral infection that causes a severe flu-like illness and sometimes a potentially lethal complication called severe dengue. The incidence of dengue

Dengue Fever - National Institute of Allergy and Infectious Dengue fever is an infectious disease carried by mosquitoes and caused by any of four related dengue viruses. This disease used to be called "break-bone" fever because it sometimes

Dengue - Global situation - World Health Organization (WHO) Dengue virus is transmitted to humans through the bite of infected mosquitoes typically in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.

¿Qué es el dengue y cómo se trata? - World Health Organization El dengue grave es una complicación potencialmente mortal, pero su diagnóstico clínico precoz y una atención clínica cuidadosa por personal médico y de enfermería experimentado suele

Dengue and severe dengue WPRO - World Health Organization Dengue is a viral infection transmitted to humans through the bite of infected mosquitoes, primarily through *Aedes aegypti* mosquitoes and, to a lesser extent, *Aedes*

Dengue- Global situation - World Health Organization (WHO) The global incidence of dengue has markedly increased over the past two decades, posing a substantial public health challenge.

From 2000 to 2019, the World Health

Dengue - Situación mundial El dengue es una enfermedad vírica que se transmite al ser humano por la picadura de mosquitos infectados, típicamente en climas tropicales y subtropicales de todo el mundo,

Dengue - World Health Organization (WHO) WHO fact sheet on dengue, providing information on symptoms, diagnostics and treatment, global burden, transmission, risk factors, prevention and control and WHO's work in

Dengue y dengue grave - World Health Organization (WHO) El dengue es una infección vírica transmitida por mosquitos. En las últimas décadas ha aumentado enormemente la incidencia de dengue en el mundo

Dengue and severe dengue - World Health Organization (WHO) Dengue is a self-limiting febrile illness with symptoms ranging from extremely mild (asymptomatic) to severe. Symptoms of dengue may be observed around 4–10 days after the

Dengue and severe dengue - World Health Organization (WHO) Dengue is a mosquito-borne viral infection that causes a severe flu-like illness and sometimes a potentially lethal complication called severe dengue. The incidence of dengue

Dengue Fever - National Institute of Allergy and Infectious Dengue fever is an infectious

disease carried by mosquitoes and caused by any of four related dengue viruses. This disease used to be called "break-bone" fever because it sometimes

Dengue - Global situation - World Health Organization (WHO) Dengue virus is transmitted to humans through the bite of infected mosquitoes typically in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.

¿Qué es el dengue y cómo se trata? - World Health Organization El dengue grave es una complicación potencialmente mortal, pero su diagnóstico clínico precoz y una atención clínica cuidadosa por personal médico y de enfermería experimentado suele

Dengue and severe dengue WPRO - World Health Organization Dengue is a viral infection transmitted to humans through the bite of infected mosquitoes, primarily through *Aedes aegypti* mosquitoes and, to a lesser extent, *Aedes*

Dengue- Global situation - World Health Organization (WHO) The global incidence of dengue has markedly increased over the past two decades, posing a substantial public health challenge. From 2000 to 2019, the World Health

Dengue - Situación mundial El dengue es una enfermedad vírica que se transmite al ser humano por la picadura de mosquitos infectados, típicamente en climas tropicales y subtropicales de todo el mundo,

Dengue - World Health Organization (WHO) WHO fact sheet on dengue, providing information on symptoms, diagnostics and treatment, global burden, transmission, risk factors, prevention and control and WHO's work in

Dengue y dengue grave - World Health Organization (WHO) El dengue es una infección vírica transmitida por mosquitos. En las últimas décadas ha aumentado enormemente la incidencia de dengue en el mundo

Dengue and severe dengue - World Health Organization (WHO) Dengue is a self-limiting febrile illness with symptoms ranging from extremely mild (asymptomatic) to severe. Symptoms of dengue may be observed around 4-10 days after the

Dengue and severe dengue - World Health Organization (WHO) Dengue is a mosquito-borne viral infection that causes a severe flu-like illness and sometimes a potentially lethal complication called severe dengue. The incidence of dengue

Dengue Fever - National Institute of Allergy and Infectious Dengue fever is an infectious disease carried by mosquitoes and caused by any of four related dengue viruses. This disease used to be called "break-bone" fever because it sometimes

Dengue - Global situation - World Health Organization (WHO) Dengue virus is transmitted to humans through the bite of infected mosquitoes typically in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.

¿Qué es el dengue y cómo se trata? - World Health Organization El dengue grave es una complicación potencialmente mortal, pero su diagnóstico clínico precoz y una atención clínica cuidadosa por personal médico y de enfermería experimentado suele

Dengue and severe dengue WPRO - World Health Organization Dengue is a viral infection transmitted to humans through the bite of infected mosquitoes, primarily through *Aedes aegypti* mosquitoes and, to a lesser extent, *Aedes*

Dengue- Global situation - World Health Organization (WHO) The global incidence of dengue has markedly increased over the past two decades, posing a substantial public health challenge. From 2000 to 2019, the World Health

Dengue - Situación mundial El dengue es una enfermedad vírica que se transmite al ser humano por la picadura de mosquitos infectados, típicamente en climas tropicales y subtropicales de todo el mundo,